Yamada, I <br/><br/>
Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.  [electronic resource] 

 -  Journal of viral hepatitis  Feb 2012 
 - e112-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1365-2893 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2893.2011.01514.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiviral Agents--administration & dosage<br/>Drug Resistance, Viral<br/>Female<br/>Genotype<br/>Hepacivirus--classification<br/>Hepatitis C--drug therapy<br/>Humans<br/>Japan<br/>Male<br/>Middle Aged<br/>Oligopeptides--administration & dosage<br/>RNA, Viral--blood<br/>Time Factors<br/>Viral Load